Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183971 | 0.85 | CA2 (0.42) | BACE1PTGESCA2GRIN2DGRIN3B | |
| SCHEMBL184509 | 0.79 | BACE1 (0.34) | BACE1ATMPTGESHDAC1HDAC3 | |
| SCHEMBL185295 | 0.74 | ACLY (0.48) | BACE1CA2 | |
| SCHEMBL1800473 | 0.74 | GRIN2D (0.47) | BACE1PTGESHDAC1HDAC3HDAC2 | |
| SCHEMBL1799273 | 0.72 | BACE1 (0.40) | BACE1PTGESHDAC1HDAC3HDAC2 | |
| SCHEMBL8127646 | 0.71 | HDAC1 (0.53) | BACE1PTGESHDAC1HDAC3HDAC2 | |
| SCHEMBL27605380 | 0.70 | GRIN2D (0.49) | BACE1PTGESHDAC1HDAC3HDAC2 | |
| SCHEMBL1802804 | 0.70 | BACE1 (0.40) | BACE1PTGESHDAC1HDAC3HDAC2 | |
| SCHEMBL4695439 | 0.69 | HDAC3 (0.49) | BACE1PTGESHDAC1HDAC3HDAC2 | |
| SCHEMBL19208209 | 0.69 | TSHR (0.48) | BACE1PTGESHDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2297103-B1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | BACE1 580/4885ATM 4129/4885PTGES 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.